Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
HA121-28
i
Other names:
HA121-28, HA121 28, HA-121 28, SYHA121-28
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
CSPC Pharma
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
›
Associations
(1)
News
Trials
Filter by
Latest
over2years
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=83, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
over 2 years ago
Enrollment open
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
HA121-28
almost3years
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=83, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Initiation date: Nov 2021 --> Mar 2022 | Trial primary completion date: Mar 2023 --> Oct 2023
almost 3 years ago
Trial initiation date • Trial primary completion date
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
HA121-28
3years
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=83, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
3 years ago
Clinical • New P2 trial
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
HA121-28
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login